Chalcone-inspired rA1 /A2A adenosine receptor ligands: Ring closure as an alternative to a reactive substructure

Chem Biol Drug Des. 2022 Mar;99(3):416-437. doi: 10.1111/cbdd.13999. Epub 2021 Dec 27.

Abstract

Over the past few years, great progress has been made in the development of high-affinity adenosine A1 and/or A2A receptor antagonists-promising agents for the potential treatment of Parkinson's disease. Unfortunately, many of these compounds raise structure-related concerns. The present study investigated the effect of ring closures on the rA1 /A2A affinity of compounds containing a highly reactive α,β-unsaturated carbonyl system, hence providing insight into the potential of heterocycles to address these concerns. A total of 12 heterocyclic compounds were synthesised and evaluated in silico and in vitro. The test compounds performed well upon qualitative assessment of drug-likeness and were generally found to be free from potentially problematic fragments. Most also showed low/weak cytotoxicity. Results from radioligand binding experiments confirm that heterocycles (particularly 2-substituted 3-cyanopyridines) can replace the promiscuous α,β-unsaturated ketone functional group without compromising A1 /A2A affinity. Structure-activity relationships highlighted the importance of hydrogen bonds in binding to the receptors of interest. Compounds 3c (rA1 Ki = 16 nM; rA2A Ki = 65 nM) and 8a (rA1 Ki = 102 nM; rA2A Ki = 37 nM), which both act as A1 antagonists, showed significant dual A1 /A2A affinity and may, therefore, inspire further investigation into heterocycles as potentially safe and potent adenosine receptor antagonists.

Keywords: Parkinson's disease; adenosine A1/A2A receptor antagonist; cyanopyridine; heterocycle; ring closure.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzylidene Compounds / chemical synthesis
  • Benzylidene Compounds / chemistry
  • Benzylidene Compounds / metabolism
  • Chalcone / chemical synthesis
  • Chalcone / chemistry*
  • Chalcone / metabolism
  • Drug Design
  • Humans
  • Ligands
  • Protein Binding
  • Rats
  • Receptor, Adenosine A1 / chemistry*
  • Receptor, Adenosine A1 / metabolism
  • Receptor, Adenosine A2A / chemistry*
  • Receptor, Adenosine A2A / metabolism
  • Structure-Activity Relationship

Substances

  • Benzylidene Compounds
  • Ligands
  • Receptor, Adenosine A1
  • Receptor, Adenosine A2A
  • Chalcone